Previous 10 | Next 10 |
home / stock / cslly / cslly news
The steep correction of December 2018 now seems a distant memory. Project $1M made new all time highs in February as a result of renewed optimism on China and a swag of positive results from portfolio components. Overall, the portfolio finished up some 4.96% for the month, marginally outperf...
Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness MONTREAL and KING OF PRUSSIA, Pa. , Feb. 4, 2019 /PRNewswire/ -- The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring t...
KING OF PRUSSIA, Pa. , Jan. 16, 2019 /PRNewswire/ -- Forbes magazine has named global biotechnology leader CSL Limited as one of The Best Employers for Diversity in the United States . CSL, the fifth largest biotechnology company in the world, ranked No. 39 in the leading bus...
KING OF PRUSSIA, Pa. , Jan. 7, 2019 /PRNewswire/ -- Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, today announced that it will present at the 2019 J.P. Morgan Annual Healthcare Conference. Ch...
CSL Limited ( CSLLY ) is the largest plasma biotech in the world. Growth and profitability are unbelievable. This stock is down over $50 Australian dollars this year. You need to know this high growth biotech even if its shares are still expensive. The stock trades for AU $175.65, there ar...
KING OF PRUSSIA, Pa. , Dec. 6, 2018 /PRNewswire/ -- Paul Perreault, CEO and Managing Director of CSL Limited, is one of the Philadelphia Business Journal's Most Admired CEOs for 2018, recognizing his patient-focused leadership of the world's fifth largest biotechnology company. ...
HOLLY SPRINGS, N.C. , Nov. 16, 2018 /PRNewswire/ -- Seqirus, a wholly owned subsidiary of CSL Limited and a global leader in influenza prevention, today announced a $140M expansion of its Holly Springs manufacturing facility in North Carolina . The Holly Springs facility is at the ...
SUMMIT, N.J. , Nov. 16, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that its cell-based quadrivalent influenza vaccine (QIVc) was 36.2 percent more effective than standard egg-based quadrivalent vaccin...
SUMMIT, N.J. , Oct. 23, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced the U.S. Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in people six months of age and older, 1 extending the company's ...
MAIDENHEAD, England , October 19, 2018 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today announced that its cell-based quadrivalent influenza vaccine (QIVc) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the Europe...
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) ...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy Canada NewsWire First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditi...
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure Canada NewsWire ST. GALLEN, SWITZERLAND , March 19, 2024 /CNW/ -- CSL Vifor today a...